[email protected]
CDI - Contrive Datum Insights
Press ReleaseHealthcare Services

Home Infusion Therapy Market to Reach USD 82.96 billion by 2034 at 8% CAGR

Contrive Datum Insights has published "Home Infusion Therapy Market Size, Share & Industry Analysis, By Therapy type (Anti-Infective Therapy, Parenteral Nutrition, Enteral Nutrition, Immunoglobulin Therapy, Chemotherapy, Pain Management, Hydration Therapy, Inotropic and Cardiac Therapy, Specialty Biologics and Rare Disease Therapies), Product (Infusion Pumps, IV Sets and Administration Sets, IV Catheters and Access Devices, IV Bags and Containers, Needleless Connectors and Accessories), Service type (Pharmacy Compounding and Dispensing, Skilled Nursing and Clinical Services, Equipment Rental and Supply, Patient Training and Care Coordination, Remote Patient Monitoring and Telepharmacy), Route of administration (Intravenous, Subcutaneous, Enteral, Epidural and Intrathecal, Intramuscular), Indication (Infectious Diseases, Cancer, Primary and Secondary Immunodeficiency, Gastrointestinal Disorders and Short Bowel Syndrome, Neurological and Autoimmune Disorders, Hemophilia and Bleeding Disorders, Cardiovascular Disorders, Diabetes, Chronic Pain), Provider type (Independent Home Infusion Pharmacies, Hospital-Based Infusion Providers, Payer-Owned Infusion Providers, Specialty Pharmacy-Affiliated Providers, Home Health Agency-Based Providers), Patient age group (Pediatric, Adult, Geriatric), Payer type (Medicare, Medicaid and Government Programs, Commercial Insurance, Out-of-Pocket and Self-Pay), Care setting (Patient Home, Ambulatory Infusion Suites, Assisted Living Facilities, Skilled Nursing Facilities), Duration of therapy (Short-Term (Acute) Therapy, Long-Term (Chronic) Therapy, Intermittent and Episodic Therapy), and Regional Forecast, 2026-2034". The study sizes the global home infusion therapy market at USD 41.5 billion in 2025 and projects growth from USD 44.82 billion in 2026 to USD 82.96 billion by 2034, a compound annual growth rate of 8% across the forecast period.

PUNE, INDIA — 18 NOVEMBER 2026 — CONTRIVE DATUM INSIGHTS

Market reaches USD 82.96 billion by 2034, up from USD 41.5 billion in 2025, at a 8% CAGR.

Fastest growth: Specialty Biologics and Rare Disease Therapies at 12.75% a year.

Anti-Infective Therapy leads therapy type with 26.99% of 2025 revenue.

Home infusion therapy is the delivery of intravenous, subcutaneous, enteral and other infused drugs and nutrition to patients in their own home or other non-hospital settings. It includes the pharmacy compounding, nursing visits, pumps and supplies that make this care possible, and it covers anti-infective, nutrition, immunoglobulin, chemotherapy, pain and specialty biologic therapies. Buyers are insurers and government programmes, health systems that refer patients out of hospital, and patients who pay directly.

Shift of infusion care from hospitals to the home

Shift of infusion care from hospitals to the home is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 8% a year, the therapy type lines exposed to it move fastest: Specialty Biologics and Rare Disease Therapies compounds at 12.75%, taking its share of revenue from 12% to 17.85% and its value from USD 4.98 billion to USD 14.81 billion.

The study also runs a bull case: faster site-of-care transfer, wider payer coverage for home infusion drugs and quicker uptake of subcutaneous biologics lift growth above the base path. That path ends 2034 at USD 91.92 billion, above the USD 82.96 billion base case.

On the downside, slower coverage expansion, nursing shortages and tighter payer controls on infusion drugs hold growth below the base path, which would hold 2034 revenue to USD 74 billion. Anti-Infective Therapy, which carries 26.99% of 2025 revenue, already grows at only 6.73% against the market's 8%, so the largest part of the base is also its slowest.

Anti-Infective Therapy Scale Against Specialty Biologics and Rare Disease Therapies Momentum

The therapy type axis, not the regional one, is what divides the field. Anti-Infective Therapy is the volume position, 26.99% of 2025 revenue at USD 11.2 billion, holding 24.3% through 2034, and it is defended by scale. Specialty Biologics and Rare Disease Therapies is the growth position at 12.75%, and it is open. Strength in one does not carry into the other.

Further Report Findings

* * * By therapy type, the largest line in 2025 was Anti-Infective Therapy, at 26.99% of revenue and USD 11.2 billion. * No therapy type line grows faster than Specialty Biologics and Rare Disease Therapies, at a projected 12.75%. * By product, Infusion Pumps led in 2025 with 30% of revenue at USD 12.45 billion, while Needleless Connectors and Accessories grows fastest at 9.16%. * By service type, Pharmacy Compounding and Dispensing led in 2025 with 38% of revenue at USD 15.77 billion, while Remote Patient Monitoring and Telepharmacy grows fastest at 14.68%. * By route of administration, Intravenous led in 2025 with 72% of revenue at USD 29.88 billion, while Subcutaneous grows fastest at 12.37%. * By indication, Infectious Diseases led in 2025 with 24% of revenue at USD 9.96 billion, while Neurological and Autoimmune Disorders grows fastest at 13.41%. * By provider type, Independent Home Infusion Pharmacies led in 2025 with 34% of revenue at USD 14.11 billion, while Payer-Owned Infusion Providers grows fastest at 10.21%. * By patient age group, Adult led in 2025 with 56% of revenue at USD 23.24 billion, while Geriatric grows fastest at 9.75%. * By payer type, Commercial Insurance led in 2025 with 40% of revenue at USD 16.6 billion, while Out-of-Pocket and Self-Pay grows fastest at 9.16%. * By care setting, Patient Home led in 2025 with 78% of revenue at USD 32.37 billion, while Assisted Living Facilities grows fastest at 11.51%. * By duration of therapy, Long-Term (Chronic) Therapy led in 2025 with 55.01% of revenue at USD 22.83 billion. * The United States is the largest single country market at USD 20.3 billion in 2025, 48.9% of global revenue.

Every year from 2020 to 2034 is reported, with revenue and growth for each line across ten axes: by therapy type, and by product, service type, route of administration, indication, provider type, patient age group, payer type, care setting and duration of therapy. The headline total carries bear, base and bull cases at USD 74 billion and USD 91.92 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.

Regions Covered
North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa
About Contrive Datum Insights

Contrive Datum Insights is a global market intelligence and consulting firm working across investment, information technology, healthcare and manufacturing markets. Every market we publish is sized twice — once top-down from the leading players and once bottom-up from the addressable base — and validated by primary interview. More about CDI.

Media contact
[email protected]
Asia Pacific
Kunjir Shyama Prestine, Sr. no. 174/1
Jagtap Diary Road, Pimple Saudagar
Pune 411017, India
+91 983 481 6757
United States
21C2 Lakeshore Dr.
Farmington, CT 06032
United States
+1 215 297 4078